Bolt Biotherapeutics, Inc. (BOLT)

NASDAQ: BOLT · IEX Real-Time Price · USD

1.160

+0.010 (0.87%)

At close: Apr 26, 2024, 10:22 AM

1.110

-0.050 (-4.31%)

After-hours: Apr 26, 2024, 4:00 PM EDT

Bolt Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	7.88	5.73	1.26	0.23	0.22	0
Revenue Growth (YoY)	37.48%	354.68%	445.45%	7.44%	-	-
Gross Profit	7.88	5.73	1.26	0.23	0.22	0
Selling, General & Admin	22.53	22.93	18.39	9.06	5.18	2.21
Research & Development	61.54	73.12	75.66	40.36	26	9.42
Operating Expenses	84.07	96.05	94.05	49.41	31.18	11.63
Operating Income	-76.2	-90.32	-92.79	-49.18	-30.97	-11.63
Other Expense / Income	-7	-2.22	5.8	11.55	-0.48	-0.04
Pretax Income	-69.2	-88.1	-98.59	-60.73	-30.49	-11.59
Net Income	-69.2	-88.1	-98.59	-60.73	-30.49	-11.59
Shares Outstanding (Basic)	38	37	33	2	2	2
Shares Outstanding (Diluted)	38	37	33	2	2	2
Shares Change	1.21%	12.54%	1479.05%	5.46%	20.76%	-
EPS (Basic)	-1.83	-2.36	-2.97	-28.89	-15.29	-7.02
EPS (Diluted)	-1.83	-2.36	-2.97	-28.89	-15.29	-7.02
Free Cash Flow	-69.73	-78.46	-59.4	-50.57	-26.85	-10.16
Free Cash Flow Per Share	-1.84	-2.10	-1.79	-24.05	-13.47	-6.16
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-967.45%	-1576.56%	-7364.13%	-21290.91%	-14404.19%	-
Profit Margin	-878.58%	-1537.76%	-7824.68%	-26289.18%	-14180.00%	-
Free Cash Flow Margin	-885.36%	-1369.47%	-4714.60%	-21891.77%	-12488.84%	-
EBITDA	-64.39	-83.21	-94.92	-58.22	-29.16	-11.29
EBITDA Margin	-817.56%	-1452.38%	-7533.25%	-25205.19%	-13561.86%	-
Depreciation & Amortization	4.81	4.89	3.67	2.5	1.33	0.3
EBIT	-69.2	-88.1	-98.59	-60.73	-30.49	-11.59
EBIT Margin	-878.58%	-1537.76%	-7824.68%	-26289.18%	-14180.00%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).